Compare COOK & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | ZTEK |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.7M | 68.8M |
| IPO Year | 2021 | 2022 |
| Metric | COOK | ZTEK |
|---|---|---|
| Price | $28.17 | $0.59 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $58.00 | N/A |
| AVG Volume (30 Days) | ★ 535.0K | 123.0K |
| Earning Date | 03-05-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $559,520,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.54 |
| 52 Week High | $35.56 | $1.84 |
| Indicator | COOK | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 79.73 | 41.45 |
| Support Level | $0.98 | $0.55 |
| Resistance Level | N/A | $0.67 |
| Average True Range (ATR) | 1.45 | 0.05 |
| MACD | 3.40 | 0.00 |
| Stochastic Oscillator | 77.71 | 35.76 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.